CARM1 is a cancer-relevant protein arginine methyltransferase that regulates many aspects of transcription. Its pharmacological inhibition is a promising anti-cancer strategy. Here SKI-73 is presented as a CARM1 chemical probe with pro-drug properties. SKI-73 can rapidly penetrate cell membranes and then be processed into active inhibitors, which are retained intracellularly with 10-fold enrichment for days. These compounds were characterized for their potency, selectivity, modes of action, and on-target engagement. SKI-73 recapitulates the effect of CARM1 knockout against breast cancer cell invasion. Single-cell RNA-seq analysis revealed that the SKI-73-associated reduction of invasiveness act via altering epigenetic plasticity and suppressing the invasion-prone subpopulation. Interestingly, SKI-73 and CARM1 knockout alter the epigenetic plasticity with remarkable difference, arguing distinct modes of action between the small-molecule and genetic perturbation. We therefore discovered a CARM1-addiction mechanism of cancer metastasis and developed a chemical probe to target this process.
Introduction
Numerous biological events are orchestrated epigenetically upon defining cellular fates. (Atlasi and Stunnenberg, 2017; Berdasco and Esteller, 2019) Among key epigenetic regulators are protein methyltransferases (PMTs), which can render downstream signals by modifying specific Arg or Lys residues of their substrates with S-adenosyl-L-methionine (SAM) as a methyl donor cofactor. (Luo, 2018) Significant efforts have been made to identify the PMT-dependent epigenetic cues that are dysregulated or addicted under specific disease settings such as cancer. (Berdasco and Esteller, 2019) Many PMTs are implicated as vulnerable targets against cancer malignancy. (Kaniskan et al., 2018; Luo, 2018) The pro-cancerous mechanism of these PMTs can be attributed to their methyltransferase activities via individual or combined effects of upregulating oncogenes, downregulating tumor suppressors, and maintaining cancer-cell-addicted homeostasis. (Berdasco and Esteller, 2019; Blanc and Richard, 2017) Pharmacological inhibition of these epigenetic events thus presents promising anti-cancer strategies, (Berdasco and Esteller, 2019) as exemplified by the development of the clinical inhibitors of DOT1L, (Bernt et al., 2011; Daigle et al., 2011 ) EZH2 (Kim et al., 2013; Konze et al., 2013; McCabe et al., 2012; Qi et al., 2012; Qi et al., 2017) , and PRMT5. (Bonday et al., 2018; Chan-Penebre et al., 2015) Protein arginine methyltransferases (PRMTs) act on their substrates to yield three different forms of methylated arginine: asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and monomethylarginine (MMA)---the terminal products of Type I, II and III PRMTs, respectively. (Blanc and Richard, 2017; Yang and Bedford, 2013) Among the important Type I PRMTs is CARM1 (PRMT4), which regulates multiple aspects of transcription by methylating diverse targets including RNAPII, SRC3, C/EBPβ, PAX3/7, SOX2/9, RUNX1, Notch1, p300, CBP, p/CIP, Med12, and BAF155. (Blanc and Richard, 2017; Hein et al., 2015; Vu et al., 2013; Wang et al., 2015; Wang et al., 2014; Yang and Bedford, 2013) The physiological function of CARM1 has been linked to differentiation and maturation of embryonic stem cells to immune cells, adipocytes, chondrocytes, myocytes, and lung tissues. (Blanc and Richard, 2017; Yang and Bedford, 2013) The requirement of CARM1 is implicated in multiple cancers with its methyltransferase activity particularly addicted by hematopoietic malignancies and metastatic breast cancer. (Drew et al., 2017; Greenblatt et al., 2018; Nakayama et al., 2018; Wang et al., 2014) Our prior efforts using in vivo mouse and in vitro cell models uncovered the role of CARM1 in promoting breast cancer metastasis. (Wang et al., 2014) Mechanistically, CARM1 methylates Arg1064 of BAF155 and thus facilitates the recruitment of the BAF155-containing SWI/SNF complex to a specific subset of gene loci essential for breast cancer metastasis. CARM1 thus emerges as a novel anti-cancer target. (Wang et al., 2014) While this cancer relevance inspired the development of CARM1 inhibitors, (Kaniskan et al., 2018; Scheer et al., 2019) many small-molecule CARM1 inhibitors lack target selectivity or cellular activity (Kaniskan et al., 2018 )---two essential criteria of chemical probes. (Frye, 2010) To the best of our knowledge, EZM2302, (Drew et al., 2017; Greenblatt et al., 2018 ) TP-064 (Nakayama et al., 2018) and SKI-73 (www.thesgc.org/chemical-probes/SKI-73) are the only selective and cell-active CARM1 chemical probes, which were developed by Epizyme, Takeda/SGC(Structural Genomic Consortium), and our team, respectively. EZM2302 and TP-064 were developed through conventional small-molecule scaffolds occupying the substrate-binding pocket of CARM1. (Drew et al., 2017; Greenblatt et al., 2018; Nakayama et al., 2018) The potential utility of EZM2302 and TP-064 is implicated by their selective anti-proliferative effects on hematopoietic cancer cells, in particular multiple myeloma cells. (Drew et al., 2017; Greenblatt et al., 2018; Nakayama et al., 2018) However, definitive molecular mechanisms of the CARM1 addiction in these contexts remain elusive. (Greenblatt et al., 2018) Here we report the characterization and novel utility of SKI-73---a chemical probe of CARM1 with pro-drug properties. SKI-73 can readily penetrate cell membranes and then be processed into two active CARM1 inhibitors containing 6′−homosinefungin (HSF) as their core scaffold. (Scheer et al., 2019; Wu et al., 2016) Notably, the two inhibitors can be accumulated inside cells at remarkable high concentrations and for a prolonged period. The potency, selectivity, modes of action, on-target engagement, and off-target effects of these compounds were characterized with multiple orthogonal assays in vitro and under cellular settings. The pharmacological inhibition of CARM1 by SKI-73 recapitulates the anti-invasion effect of the genetic perturbation of CARM1. In the context of cellular heterogeneity, we developed a cell-cycle-aware algorithm for single-cell RNA-seq (scRNAseq) analysis and dissected the invasion-prone subset of breast cancer cells that is sensitive to SKI-73 treatment. Our scRNA-seq analysis provides the unprecedented insight that pharmacological inhibition of CARM1 alters epigenetic plasticity and suppresses invasion by suppressing the most invasive subpopulation of breast cancer cells.
Results

Development of 6′−homosinefungin derivatives as potent and selective CARM1 inhibitors.
Upon developing cofactor-competitive PMT inhibitors, (Wu et al., 2016; Zheng et al., 2012) we identified 6′−homosinefungin (HSF, 1) for its general high affinity to Type I PRMTs (Fig. 1a,b,   S1 ). As a SAM mimic, 1 binds to the Type I PRMTs---PRMT1, CARM1, PRMT6 and PRMT8---with IC 50 of 13~300 nM (Fig. 1a,c , Table S1 ). Its relative affinity to Type I PRMTs aligns with that of the SAM mimics SAH and SNF (around 20-fold lower IC 50 of 1 versus SAH and SNF, Fig. 1a ,c, Table S1 ). This observation argues that 1 retains the structural features of SAH and SNF to engage PRMTs and meanwhile leverages its 6′-methyleneamine group for additional interaction. Strikingly, the HSF derivative 2a, which was synthesized via the same precursor 3 (Fig. 1b, S1 ), preferentially binds to CARM1 with IC 50 = 30 ± 3 nM and > 10-fold selectivity over other 7 human PRMTs and 26 methyltransferases of other classes (Fig. 1c , Table S1 ). The structural difference between 2a and 1 (Fig. 1b) suggests that the N-benzyl substituent enables 2a to engage CARM1 via a distinct mechanism (see results below). This engagement is expected to be maintained by 5a, an amide derivative of 2a prepared from the common precursor 3 and then the intermediate 4 (Fig. 1b, S2 ).
Here 5a shows an IC 50 of 43 ± 7 nM against CARM1 and a >10-fold selectivity over the panel of 33 diverse methyltransferases (Fig. 1c , Table S1 ). In comparison, the negative control compounds 2b (Bn-SNF) (Zheng et al., 2012) and 5b (Figure 1b, S3 ), which differ from 2a and 5a only by the 6′-methylene group, poorly inhibit CARM1 (IC 50 > 25 µM and 1.91 ± 0.03 µM) (Fig. 1c , Table S1 ).
The dramatic increase of the potency of 2a and 5a in contrast to 2b and 5b supports an essential role of the 6′-methylene moiety on binding CARM1. Distinguished from SAM mimics SAH, SNF and 1 as nonspecific PMT inhibitors, 2a and 5a were developed as potent and selective SAM analog inhibitors of CARM1 (Fig. 1c , Table S1 ). , 1) . b, Structures and synthetic outline of HSF derivatives 2a and 5a, and their structurally-related control compounds 2b and 5b. c, IC 50 heat-map of SAM analogs against 34 methyltransferases. HSF derivatives 2a and 5a were identified as potent and selective inhibitors of CARM1; 2b and 5b as their respective control compounds.
Modes of interaction of 6′−homosinefungin derivatives as CARM1 inhibitors. With 2a and 5a
characterized as CARM1 inhibitors, we leveraged orthogonal in vitro assays to explore their modes of interaction (Fig. 2a) . CARM1 inhibition by 2a and 5a was assessed in the presence of various concentrations of SAM cofactor and H3 peptide substrate (Fig. 2b,c) . IC 50 values of 2a and 5a showed a linear positive correlation with SAM concentrations, as expected for SAM-competitive inhibitors. Luo, 2018; Zheng et al., 2012) The K d values of 2a and 5a (K d,2a = 17 ± 8 nM; K d,5a = 9 ± 5 nM) were extrapolated from the y-axis intercepts upon fitting the equation (Fig. 2b) . (Segel, 1993 ) K m,SAM of 0.21 ± 0.09 µM and 0.28 ± 0.14 µM (an averaged K m,SAM = 0.25 µM) for competition with 2a and 5a can also be derived through the ratio of the y-axis intercepts to the slopes ( Fig. 2b and Supplementary Methods). (Segel, 1993) In contrast, the presence of the H3 peptide substrate had negligible effect on the binding of 2a and 5a, indicating their substrate-noncompetitive character (Fig. 2c) . The SAM analogs 2a and 5a were thus characterized as SAM-competitive, substrate-noncompetitive inhibitors of CARM1.
The CARM1-binding kinetics of 2a and 5a were also examined using surface plasmon resonance (SPR) (Fig. 2d) . The SPR signal progression of 2a and 5a fits with a biphasic rather mono-phasic binding mode with the lower K d1,2a = 0.06 ± 0.02 µM, K d1,5a = 0.10 ± 0.01 µM, and the higher K d2,5b = 0.54 ± 0.07 µM, K d2,2a = 0.4 ± 0.1 µM, likely due to multi-phase binding kinetics of 2a and 5a (Figure 2d ). In vitro thermal shift assay (Blum et al., 2014) Structural rationale of 6′−homosinefungin derivatives as CARM1 inhibitors. To further seek structural rationale of 5a and 2a for CARM1 inhibition, we solved the X-ray structure of CARM1 in complex with 5a and modeled the CARM1 binding of 2a (Fig. 3 , Supplementary Results and Methods). The overall topology of the CARM1-5a complex is indistinguishable with a V-shape subunit of CARM1 dimer in complex with SNF and 1 ( Figure S4 , S5 and Table S2 -4)---the Rossmann fold of Class I methyltransferases (Fig. 3a) . (Luo, 2018) However, 5a adopts a noncanonical pose with its 6′-N-benzyl moiety in a binding pocket that used to be occupied by the α -amino carboxylate moiety of canonical ligands such as SAH, SNF and 1 (Fig. 3b, S4 and Table   S2 -4), while the α -amino methoxyphenethyl amide moiety of 5a protrudes into the substratebinding pocket. (Boriack-Sjodin et al., 2016; Sack et al., 2011) This noncanonical mode is consistent with the SAM-competitive character of 5a (Fig. 2b) . Under the canonical setting, the guanidinium moiety of Arg168 forms a salt bridge with the carboxylic moiety of canonical ligands ( Fig. 3c ). In contrast, Arg168 in the CARM1-5a complex has to adopt an alternative orientation (two possible configurations), accompanied by an altered conformation of Glu257, to accommodate the 6′-Nbenzyl moiety of 5a (Fig. 3c ). The α -amino amide moiety of 5a also engages CARM1 through the combined outcomes of a hydrogen-bond network with Glu266 and His414 and hydrophobic interactions with Phe152 and Tyr261 (Fig. 3d) . Interestingly, the overlaid structures of CARM1 in complex with 5a and a substrate peptide implicate a steric clash and thus a potential competitivebinding mode between 5a and a CARM1 substrate (Fig. 3e) . However, the apparent substratenoncompetitive character of 5a ( Figure 2c ) suggests that this steric clash might be avoided if there is no significant energy penalty for the substrate Arg to adopt alternative conformation(s).
The binding mode of the CARM1-2a complex was modeled via molecular docking followed by molecular dynamics ( Figure 3. Crystal structure or molecular modeling of CARM1 in complex with 5a and 2a. a, Overview of the Rossmann fold in the X-ray structure of CARM1 with 5a. b, Comparison of the binding modes between 5a (noncanonical) and SNF (canonical). The structure of SNF was extracted from a CARM1-SNF-H3R17 complex (PDB 5DX0). c, Key interactions between CARM1 and ligands in canonical and noncanonical binding modes. The differentiated interactions are highlighted in grey (CARM1) and blue (SNF) for the canonical mode; green (CARM1) and orange (5a) for the noncanonical mode. d, Additional interactions via the α -amino amide moiety of 5a. e, Steric clash between the α -amino amide moiety of 5a and an Arg substrate. The structure of the Arg substrate was extracted from a CARM1-SNF-H3R17 complex (PDB 5DX0). f. Two modeled binding poses (BP1 and BP2) of 2a upon binding CARM1.
A pro-drug-like 6′−homosinefungin derivative as a cell-active CARM1 inhibitor. While the in vitro characterization demonstrated the potency and selectivity of 2a and 5a against CARM1, we anticipated their poor membrane permeability as observed for structurally-related analogs such as SAH and SNF (Fig. 1a) . (Boriack-Sjodin et al., 2016; Sack et al., 2011) The lack of membrane penetration is likely due to their primary amine moiety, which has pKa of ~ 10 and is fully protonated at a physiological pH of 7.4. Given the essential roles of the 9′−amine moiety of 2a and 5a in CARM1 binding (Fig. 3d) , we envisioned overcoming the membrane permeability issue via a pro-drug strategy by cloaking this amine moiety with a redox-triggered trimethyl-locked quinone propionate moiety (TML, Fig. 4a ). (Levine and Raines, 2012) We thus prepared 6a as well as its control compound 6b by derivatizing 5a and 5b with the TML moiety (Fig. S2, S3) . To assess the cellular activity of 6a, we relied on our prior knowledge that CARM1 methylates the Arg1064 of BAF155, a core component of the SWI/SNF chromatin remodeling complex, and CARM1 knockout abolishes this posttranslational modification in MCF-7 cells. (Wang et al., 2014) Treatment of MCF-7 cells with 10 µM of 6a fully suppressed this methylation mark, whereas treatment with 2a and 5a did not affect this mark (Fig. 4b) . We thus demonstrated the prodrug-like cellular activity of 6a. (Fig. 4c) . While we anticipated the conversion of the pro-drug 6a into 5a, a striking finding is that 6a can also be readily processed into 2a inside cells (Fig. 4c) . Remarkably, > 100 μ M of 2a can be accumulated inside cells for 2 days after 6-h treatment with a single dose of 5~10 µM 6a. This observation likely reflects a slow efflux and thus effective intracellular retention of 2a due to its polar α -amino acid zwitterion moiety. Given that cellular CARM1 inhibition is involved with multiple species (2a, 5a and 6a) in competition with SAM, we modeled the ligand occupancy of cellular CARM1 on the basis of their
.25 µM) and MS-quantified intracellular concentrations (Fig. 4d , eqs. S5-S7, Supplementary Methods). The SAM cofactor, whose intracellular concentration was determined to be 89 ± 16 µM (Fig. 4c,d ), is expected to occupy > 99.5% CARM1 with residual < 0.5% as the apo-enzyme under a native setting. With single doses of 6a of 2.5~10 µM, the combined CARM1 occupancy by 2a, 5a and their pro-drug precursor 6a rapidly reached the plateaus of >95% within 6 h, and was maintained at this level for at least 48 h (Fig. 4e) . Notably, the treatment of 6a as low as 0.5 µM is sufficient to reach 60% target engagement within 10 h and maintain this occupancy for 48 h (Fig. 4e) . The time-and dosedependent progression of the CARM1 occupancy by these ligands thus provides quantitative guidance upon the treatment of MDA-MB-231 cells with 6a.
With a cellular thermal shift assay (CETSA), (Jafari et al., 2014) we further observed that the treatment of MDA-MB-231 cells with 6a but not the control compound 6b increases cellular T m and thus thermal stability of CARM1 by 4.3 ± 0.6 °C (Fig. 4f) . The distinct effect of 6a in contrast to 6b
on the cellular T m of CARM1 aligns well with the 4.1~6.2 °C difference of in vitro T m of CARM1 upon binding 2a and 5a versus SAM (Figs. 2e) . Here 6b can penetrate cell membrane and be processed into 5b and 2b in a similar manner as 6a ( Figure S11 ). These observations thus present the cellular evidence of CARM1 engagement of 2a and 5a. 2014) These methylation marks can be fully suppressed by 6a in a dose-dependent manner (Fig.   5a ). The resultant EC 50 values of 0.45~0.75 µM (Fig. 5b ) are well correlated with the modeled 60% cellular occupancy of CARM1 upon the treatment of 0.5 µM 6a for 48 h (Fig. 4e) . In contrast, the treatment of the negative control compound 6b showed no effect on these methylation marks (Fig.   5a ). We therefore demonstrated the robust use of 6a (SKI-73) as a CARM1 chemical probe and 6b
(SKI-73N) as its control compound. (Fig. 5c,d ). The treatment with ≥ 10 µM 6a reached the maximal 80% suppression on the invasion of MDA-MB-231 relative to the DMSO control, which is comparable with the phenotype of CARM1-KO (Fig. 5e) . Critically, no further inhibition by 6a on the invasiveness was observed upon its treatment of MDA-MB-231 CARM1-KO cells in comparison with the treatment with DMSO or 6b (Fig. 5e) . Notably, the treatment with 6a and 6b under the current condition has no apparent impact on the proliferation of parental and CARM1-KO MDA-MB-231 cells ( Figure S12 BAF155 methylation and PABP1 methylation, two marks of the CARM1-specific methyltransferase activity, were examined upon the treatment of 6a and its structural analog 6b (negative control compound) for 48 hours. Western Blot analysis was then conducted to quantify the relative intensities of the methylated versus total proteins (BAF155 and PABP1, two replicates with representative one shown). b, EC 50 of the methylation depletion of BAF155 and PABP1. The relative intensity of the methylated versus total BAF155 or PABP1 was plotted against log[6a] with the resultant EC 50 upon fitting a standard sigmoid curve using GraphPad Prism. c, Inhibition of cell invasion by 6a.
Inhibition of in vitro
Representative images of trans-well migration of MDA-MB-231 cells were shown upon treatment with various concentrations of 6a (SKI-73) or its control compound 6b (SKI-73N) for 16 hours. Invasive cells were fixed and stained with crystal violet. The invasiveness ratios were determined using the relative cell invasion of the treatment of 6a or 6b versus DMSO treatment. d, EC 50 of invasion inhibition by 6a. The invasiveness ratios were plotted as a function of the concentration of 6a. EC 50 of 1.3 ± 0.2 µM was obtained upon fitting a standard sigmoid curve using GraphPad Prism. e, Effect of 6a on cell invasion in combination with CARM1 KO. Representative images of trans-well migration of parent and CARM1 KO MDA-MB-231cells shown upon treatment with DMSO, 6a or 6b for 16 hours. The results were analyzed in a similar manner as described for Figs. 5c,d.
scRNA-seq and cell-cycle-aware algorithm reveals CARM1-dependent epigenetic plasticity.
Because of the advancement of scRNA-seq technology, stunning subpopulation heterogeneity has been uncovered even for well-defined cellular types. (Tanay and Regev, 2017) Table S6 -8) . Notably, the 48-hour treatment with SKI-73 (6a) or SKI-73N (6b) had no effect on the cell cycle, as indicated by the comparable cell-cycle distribution patterns between SKI-73, SKI-73N, and DMSO treatment ( Figure S18 , Table S5 ). This result is also consistent with the intact proliferation upon the treatment with SKI-73 and SKI-73N ( Figure S12 ). 
CARM1-associated epigenetic
Identification of CARM1-dependent, invasion-prone subpopulations of breast cancer cells.
Given that SKI-73 has no effect on cell cycle and proliferation of MDA-MB-231 cells under the current treatment dose and duration, we envision that the invasion capability of MDA-MB-231 cells mainly arises from an invasion-prone subset, 80% of which is depleted by SKI-73 treatment ( and SKI-73N, we classified the freshly-harvested invasive cells into G0/G1, S and G2/M stages ( Figure S51 , Table S5 ). Through the correlation analysis between the invasion cells and the subpopulations within each cell-cycle stage (Figure 6d , S40, S41, S47, S48, S54, S55), we readily revealed the subsets whose transcriptional signatures closely relate to those of the invasion cells including Subpopulation-6/7/8/9/14 in G0/G1-phase cells, 0/3 in S-phase cells and 1/2 of G2/Mphase cells (Table S6 -11). In the context of population analysis for the nine SKI-73-specific depleted subpopulations, Subpopulation-8/14 of G0/G1-phase cells and Subpopulation-3 in S-phase are putative invasion-prone candidates. Subpopulation 8 of G0/G1-phase cells is the most sensitive and the only subpopulation that can be depleted by around 80% with SKI-73 treatment (Figure 6c ).
Given the ~80% suppression and ~20% residual invasion capability upon SKI-73 treatment, we argue that the invasive phenotype of MDA-MB-231 cells predominantly arises from the Subpopulation-8 of G0/G1-phase cells, which only accounts for ~8% of the parental cells in G0/G1
phase or ~5% without cell-cycle awareness. Differential expression analysis further revealed the single-cell transcriptional signatures of metastasis-implicated genes (e.g. MORC4, S100A2, RPL39, IFI27, ARF6, CHD11, SDPR and KRT18) that are specific for the G0/G1-phase Subpopulation-8
and invasion cells but not other G0/G1-phase invasion-prone candidates such as Subpopulation-6/7/9/14 (Fig. 6e, S55 and Table S12 ). The remaining cells of G0/G1-phase Subpopulation-8 after SKI-73 treatment (Fig. 6c,d ) together with others (subpopulation-6/7/9/14 in G0/G1-phase cells, showed that pharmacological inhibition of CARM1 with SKI-73, but not SKI-73N, suppressed 80% invasion capability of MDA-MB-231 cells. In contrast, the pharmacological inhibition of CARM1 with SKI-73 had no effect on the proliferation of MDA-MB-231 cells. This result is consistent with the lack of anti-proliferation activities of the other two CARM1 chemical probes EZM2302 and TP-064 against breast cancer cell lines. (Drew et al., 2017; Nakayama et al., 2018) The anti-invasion efficiency of SKI-73 is in a good agreement with the intracellular occupancy and the resulting abolishment of several methylation marks of CARM1 upon the treatment of SKI-73.
Our prior work showed that the methyltransferase activity of CARM1 is required for breast cancer metastasis. (Wang et al., 2014) L.X.Q., X.C.C., and X.N. analyzed scRNA-seq data; X.C.C., M.L., W.X., L.X.Q., J.X., P.J.B.,
